Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | How should augmentation in RLS be treated? Iron, dose reduction and alternative therapies

Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses the management of augmentation in restless legs syndrome (RLS). Dr Garcia-Borreguero first recommends addressing low serum or brain iron levels and medications with dopamine antagonist effects. He explains that the dopamine agonist dose should be reduced, ideally alongside a gabapentinoid while iron takes effect. If these strategies fail, he recommends an opioid such as extended-release oxycodone. He also highlights intravenous iron as an option and dopamine D1 receptor antagonists as a potential future approach. This interview took place at Sleep Europe 2026, which was held in Maastricht, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Once augmentation has been identified the main strategy should go into first eliminate any factors that might be exacerbating it. For example the first thing to check in my opinion would be to look at the serum iron levels. I would also look at brain iron by means of an ultrasound of the substantia nigra. If in either of the two the the iron levels are reduced, I would consider the administration of iron...

Once augmentation has been identified the main strategy should go into first eliminate any factors that might be exacerbating it. For example the first thing to check in my opinion would be to look at the serum iron levels. I would also look at brain iron by means of an ultrasound of the substantia nigra. If in either of the two the the iron levels are reduced, I would consider the administration of iron. Second if the patient is being treated with antidepressants or with neuroleptics or drugs with any dopamine antagonist effect, then I would consider well I would consider the possibility of interrupting these treatments. In addition to that we have to reduce the dose of the dopamine agonist, however if we reduce the dose of the dopamine agonist, there will be an increase in symptom severity, there will we are rebound over the short term. So one of the strategies might be either to switch the dopamine agonist to a long-acting dopamine agonist, although in my opinion that will only buy time. Which is something already in desperate situations buying time is one of options, but we have to be aware we’re just buying time because the problem will occur again later on. The other option is to reduce the dose of the dopamine agonist to a combination treatment with a gabapentinoid and keep it that way until we wait for the iron to have an effect. If this combination strategy does not work then the alternative option would be in assuming that just switching to a gabapentinoid didn’t work either, then the last strategy would be to treat the patient with an opioid, with a new receptor agonist. And in Europe the one we use most is oxycodone extended release. There are other options but this is the most studied one in Europe. In addition we have data showing that the administration of intravenous iron can produce an improvement of RLS symptoms, can improve augmentation symptoms, although it might take a few months until that occurs. The problem in this condition is that the iron that you’re infusing has difficulties going through the blood-brain barrier and this is one of the abnormalities in RLS. In addition there might be drugs being developed in future, you know the basis of augmentation one of the key factors in augmentation is that there is an upregulation of dopamine type 1 receptors which are pro-nociceptive. These receptors are upregulated as a result of the long-term treatment and the administration of a dopamine type 1 antagonist has proven to to have some benefits in pilot studies so far.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.